Onconetix マネジメント

マネジメント基準チェック /04

Onconetixの CEO はRalph Schiessで、 Dec2023年に任命され、の在任期間は 1 年未満です。は、会社の株式の5.97%を直接所有しており、その価値は€ 1.33M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と1.8年です。

主要情報

Ralph Schiess

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	6.0%
経営陣の平均在職期間	1.8yrs
取締役会の平均在任期間	1.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Ralph Schiess (45 yo)

less than a year

在職期間

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	データなし	5.97% € 1.3m
Karina Fedasz	Interim Chief Financial Officer	less than a year	データなし	データなし
Brian Price	Head of Technology Strategy	4.2yrs	US$126.48k	データなし
Frank Jaeger	Senior VP of Marketing & Business Development	1.8yrs	データなし	データなし
Andrew Skibo	Global Head of Biologics Operations	3.4yrs	データなし	データなし
Theodore Yoho	Head of Business Development	3.4yrs	データなし	データなし
Ali Fattom	Head of Science & Discovery	2.2yrs	データなし	データなし
Jay Newmark	Chief Medical Officer	1.6yrs	データなし	データなし
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	データなし	5.23% € 1.2m
Donald Very	Senior VP of Commercial Research & Development	no data	データなし	データなし

1.8yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: J4T0の経営陣は経験豊富とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
John Rice	Member of Scientific Advisory Board	no data	データなし	データなし
Thomas Meier	Director	less than a year	データなし	0.040% € 8.9k
James Sapirstein	Non Executive Chairman & Lead Independent Director	2.8yrs	US$182.12k	0.042% € 9.3k
Ajit Singh	Independent Director	less than a year	データなし	0.041% € 9.1k
Sunetra Gupta	Member of Scientific Advisory Board	no data	データなし	データなし
Simon Tarsh	Independent Director	2.3yrs	US$112.62k	0.042% € 9.3k
Timothy Ramdeen	Independent Non-Executive Director	1.8yrs	US$82.67k	0.042% € 9.3k

1.8yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: J4T0の取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Onconetix マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Recent updates

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(a)(1)

Onconetix, Inc. announced that it expects to receive $27 million in funding

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04